tbuckley/cabot-search huggingface dataset:
ORGANIZATION SECTION
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphogranuloma Venereum
Authors: H.-J. B. Galbraith, C. W. Graham-Stewart, C. S. Nicol
Journal: BMJ (1957)

MIEDICAL JOURNAL(2) In spite of clinical improvement it is uncertain that evidence of complete cures from any form of treatment will be found. SummaryThe bladder neck, including the posterior urethra, is considered in some detail as a potential focus of chronic infection in recurring cystitis in women.Some practical points in relation to urethroscopy are discussed.There are common patterns of incidence and patho- logy in decades for cases of chronic frequency and cystitis.The cervix uteri is considered.Attention is called to the occurrence of gland struc- tures resembling prostatic tissue in the posterior urethra of females.A general survey of cystoscopic appearances in frequency and cystitis is made.The efficacy of local treatment is based on the need to provide the best possible drainage from the infected focus.Residual urine which resists other forms of treat- ment sometimes calls for bladder-neck resection.The uncertain value of urine reports is discussed.
Endothelial Cell–Activating Antibodies in COVID‐19
Authors: Hui Shi, Yu Zuo, Sherwin Navaz, Alyssa Harbaugh, Claire K. Hoy, Alex A. Gandhi, Gautam Sule, Srilakshmi Yalavarthi, Kelsey Gockman, Jacqueline A. Madison, Jintao Wang, Melanie Zuo, Yue Shi, Michael D. Maile, Jason S. Knight, Yogendra Kanthi
Journal: Arthritis & Rheumatology (2022)

Objective While endothelial dysfunction has been implicated in the widespread thromboinflammatory complications of COVID‐19, the upstream mediators of endotheliopathy remain, for the most part, unknown. This study was undertaken to identify circulating factors contributing to endothelial cell activation and dysfunction in COVID‐19. Methods Human endothelial cells were cultured in the presence of serum or plasma from 244 patients hospitalized with COVID‐19 and plasma from 100 patients with non–COVID‐19–related sepsis. Cell adhesion molecules (E‐selectin, vascular cell adhesion molecule 1, and intercellular adhesion molecule 1 [ICAM‐1]) were quantified using in‐cell enzyme‐linked immunosorbent assay. Results Serum and plasma from COVID‐19 patients increased surface expression of cell adhesion molecules. Furthermore, levels of soluble ICAM‐1 and E‐selectin were elevated in patient serum and correlated with disease severity. The presence of circulating antiphospholipid antibodies was a strong marker of the ability of COVID‐19 serum to activate endothelium. Depletion of total IgG from antiphospholipid antibody–positive serum markedly reduced the up‐regulation of cell adhesion molecules. Conversely, supplementation of control serum with patient IgG was sufficient to trigger endothelial activation. Conclusion These data are the first to indicate that some COVID‐19 patients have potentially diverse antibodies that drive endotheliopathy, providing important context regarding thromboinflammatory effects of autoantibodies in severe COVID‐19.
The Curriculum in Health and Physical Education
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute epiglottitis.
Authors: H P Gautam
Journal: BMJ (1970)

than a hundred countries where paraquat is now used, most of which have strict regula- tions governing the use of pesticides.In cases of human poisoning by paraquat, and in experimental animals, the highest concentrations are found in the kidneys and liver and though these organs show signs of damage there is no subsequent proliferation of any of their component cells.It would be expected that were induction of "near anaerobic conditions" a cause of the cellular reaction these organs would show more proliferation than the lungs.Measurement of ATP concentrations in paraquat poisoned animals also shows no change.There is therefore no parallel between Warburg's theory of carcinogenesis and the actions of paraquat as Drs.Stokes and Walker suggest.-Weare, etc.,
Thoracic actinomycosis
Authors: P. R. Slade, B. V. Slesser, J. Southgate
Journal: Thorax (1973)

Six cases of pulmonary infection with <i>Actinomyces Israeli</i> and one case of infection with <i>Nocardia asteroides</i> are described. The incidence of thoracic actinomycosis has declined recently and the classical presentation with chronic discharging sinuses is now uncommon. The cases described illustrate some of the forms which the disease may take. Actinomycotic infection has been noted, not infrequently, to co-exist with bronchial carcinoma and a case illustrating this association is described. Sputum cytology as practised for the diagnosis of bronchial carcinoma has helped to identify the fungi in the sputum. Treatment is discussed, particularly the possible use of oral antibiotics rather than penicillin by injection.
JAMA Reference Directories
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Overpopulation.
Authors: P Moxon
Journal: BMJ (1972)

glucose tolerance,3 which this patient had.Pantothenic acid has been used for the treatment of postoperative intestinal atony.'This patient was said to 'have hia iany episodes of abdominal distension."In pantothenic acid deficiency alphaglobulin levels are in- creased.3This patient had raised alpha-l and alpha-2 globulin levels.Pantothenic acid deficiency can produce upper abdominal pain and an increased susceptibility to infectious diseases of the respiratory tract.1These were particular features of this patient's case.She was said to have had several episodes of "an acute abdomen" in her last weeks of life and died with acute bronchitis, bronchopneumonia, herpes of the mouth and nose, and other terminal infections.As pantothenic acid is widely distributed in nature, its administration is often not con- sidered important.However, it is unstable, and as folic acid and biotin are apparently required for its utilization2 perhaps it should be given to folate deficient subjects.-Iam, etc.,
E. Grey Dimond, MD— the 'counterculture' medical educator
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigator-initiated, multicenter, randomized controlled trial.
Authors: Kouji Izumi, Takashi Shima, Koji Mita, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka, Seiji Hoshi, Takehiko Okamura, Yuko Yoshio, Hideki Enokida, Ippei Chikazawa, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Shizuko Takahara, Yoshifumi Kadono, Atsushi Mizokami
Journal: Journal of Clinical Oncology (2022)

122 Background: Enzalutamide and abiraterone plus prednisolone demonstrated improvement of survival for castration-resistant prostate cancer (CRPC). However, it remains quite unclear which agent is better in terms of efficacy and safety for Asian patients. Methods: An investigator-initiated, multicenter, randomized controlled trial was conducted in Japan. CRPC patients before chemotherapy were randomly assigned to the enzalutamide or the abiraterone plus prednisolone arm (1:1). The primary endpoint is time to prostate-specific antigen (PSA) progression and secondary endpoints include PSA response rate (≥50% decline from baseline), overall survival, radiographic progression-free survival, and safety assessment. Results: Between February 20, 2015 and July 30, 2019, 203 patients were enrolled. After randomization, 92 in the enzalutamide and 92 in the abiraterone plus prednisolone arm were treated and analyzed. Time to PSA progression was not significantly different between arms (median 21.2 and 11.9 months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 0.81, 95% CI 0.51-1.27, p = 0.1732). There was a significant difference in PSA response rate between arms (72% and 57% in the enzalutamide and the abiraterone plus prednisolone arm, respectively, p = 0.0425). There were no significant differences in overall and radiographic progression-free survival between arms (median 32.9 and 35.5months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 1.17, 95% CI 0.72-1.88, p = 0.5290 and median 17.6 and 14.0 months in the enzalutamide and the abiraterone plus prednisolone arm, respectively; hazard ration 0.92, 95% CI 0.63-1.34, p = 0.6532). Grade ≥3 of adverse events were observed in 11% and 21% in the enzalutamide and the abiraterone plus prednisolone arm, respectively ( p = 0.1044). Conclusions: Enzalutamide did not show any survival benefits compared with abiraterone plus prednisolone but showed better PSA response rate with no significant differences of severe adverse event rate for Japanese CRPC patients. Our data suggest that antecedent use of enzalutamide to abiraterone plus prednisolone have potentially clinical benefits in Asian CRPC populations. Clinical trial information: UMIN000015529.
Abstract 349: Prognostication for Out-of-Hospital Cardiogenic Cardiac Arrest Patients Using Advanced Machine Learning Technique
Authors: Tomohisa Seki, Tomoyoshi Tamura, Masaru Suzuki
Journal: Circulation (2018)

Introduction and Objective: Early prognostication for cardiogenic out-of-hospital cardiac arrest (OHCA) patients remain challenging. Recently, advanced machine learning techniques have been employed for clinical diagnosis and prognostication for various conditions. Therefore, in this study, we attempted to establish a prognostication model for cardiogenic OHCA using an advanced machine learning technique. Methods and Results: Data of a prospective multi-center cohort study of OHCA patients transported by an ambulance to 67 medical institutions in Kanto area of Japan between January 2012 and March 2013 was used in this study. Data for cardiogenic OHCA patients aged ≥18 years were retrieved and patients were grouped according to the time of calls for ambulances (training set: between January 1, 2012 and December 12, 2012; test set: between January 1, 2013 and March 31, 2013). From among 421 variables observed during the period between calls for ambulances and initial in-hospital treatments of cardiogenic OHCA, 38 prehospital factors or 56 prehospital factors and initial in-hospital factors were used for prognostication, respectively. Prognostication models for 1-year survival were established with random forest method, an advanced machine learning method that aggregates a series of decision trees for classification and regression. After 10-fold internal cross validation in the training set, prognostication models were validated using test set. Area under the receiver operating characteristics curve (AUC) was used to evaluate the prediction performance of models. Prognostication models trained with 38 variables or 56 variables for 1-year survival showed AUC values of 0.93±0.01 and 0.95±0.01, respectively. Conclusions: Prognostication models trained with advanced machine learning technique showed favorable prediction capability for 1-year survival of cardiogenic OHCA. These results indicate that an advanced machine learning technique can be applicable to establish early prognostication model for cardiogenic OHCA.
Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.
Authors: Andrew Warren Hahn, Paul Vincent Viscuse, Devaki Shilpa Surasi, Tharakeswara Bathala, Andrew James Wiele, Michael W Starbuck, Matthew T Campbell, Amishi Yogesh Shah, Eric Jonasch, Jianjun Gao, Omar Alhalabi, Kanishka Sircar, Nizar M. Tannir, Pavlos Msaouel
Journal: Journal of Clinical Oncology (2022)

351 Background: S/R mRCC is an aggressive disease that is associated with improved response to ICT. Studies performed prior to the approval of ICT demonstrated poor outcomes of S/R RCC with VEGF targeted therapies (TT). Here, we report outcomes of pts with S/R mRCC treated with VEGF TT after PD on ICT. Methods: We retrospectively reviewed the records of pts with mRCC with sarcomatoid (S), rhabdoid (R), or sarcomatoid plus rhabdoid (S+R) features who received VEGF TT after PD on ICT. Clinical endpoints of interest were time on VEGF TT and OS from treatment initiation. Directed acyclic graphs were used to identify confounders for adjustment in regression models. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated using multivariable Cox regression. Multivariable models adjusted for epithelial histology, IMDC risk, prior VEGF TT, and inclusion of cabozantinib in the post-ICT VEGF TT regimen. Results: 57 pts with metastatic S/R RCC (52 with clear cell and 5 with non-clear cell histology) received a VEGF TT after PD on ICT. 46% of pts received a VEGF TT prior to ICT. After PD on ICT, 67% of pts had IMDC intermediate-risk disease; the most commonly used VEGF TT were cabozantinib (44%), either sunitinib, pazopanib, or axitinib (24%), and a VEGF TT in combination with an ICT (21%). Pts with R RCC had significantly longer time on VEGF TT compared with S RCC (adjusted HR = 0.45, 95% CI 0.21-0.94, p = 0.034), whereas the OS comparison was inconclusive (adjusted HR = 0.77, 95% CI 0.36-1.62, p = 0.486). IMDC risk classification following ICT progression was predictive of OS (adjusted HR = 2.22, 95% CI 1.07-4.61, p = 0.032), whereas, its association with time on VEGF TT was less conclusive (adjusted HR = 1.78, 95% CI 0.88-3.60, p = 0.107). Conclusions: Patients with S/R mRCC derive clinical benefit from VEGF TT after progression on ICT, and it is similar to the benefit previously described for patients without S/R features. Our findings suggest that the type of S/R features present and IMDC risk score inform the clinical benefit that VEGF TT will produce in this setting.[Table: see text]
Response to: ‘Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis’ by Scheicht
Authors: Chetan B Mukhtyar, Bernhard Hellmich
Journal: Annals of the Rheumatic Diseases (2022)

Response to: 'Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis' by ScheichtThe European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCAassociated vasculitis were published online on 23 June 2016. 1he recommendations were cobadged with the European Renal Association.The Article Metrics on the journal website (available from https://ard.bmj.com/content/75/9/1583.altmetrics, accessed on 4 February 2022) record 667 citations and 119 217 downloads.During production, they were circulated extensively among the authors and postproduction in the vasculitis community.Indeed, they are the only set of EULAR recommendations to have been formally voted on by 88 other clinicians besides the task force in a formal validation exercise. 2On behalf of the authors, we thank Dr Scheicht for his kind words as well as for drawing our attention to the typographical error regarding the dose of methotrexate. 3n the text following statement 4 of the recommendations, we mention that methotrexate (20-25 mg/week, oral or parenteral) may be used as an alternative to cyclophosphamide in patients with less severe disease and in those with normal renal function.In the same paragraph, we mention that oral methotrexate 20-25 mg/week was non-inferior to oral cyclophosphamide at 6 months.Unfortunately, the entire steering group and the 88 other clinicians who voted on the recommendations have all overlooked that in the text following statement 7, we have made the error of saying that methotrexate (20-25 mg/kg/week) has been effectively used for maintenance therapy after induction of remission with cyclophosphamide.This is clearly an error, and the text should read 20-25 mg/week.Dr Scheicht has recommended that an additional layer of security be implemented in the production of EULAR recommendations.
Abstract 100: Intravenous Calcium as a Pressor After Hypoxic Cardiac Arrest
Authors: Joshua W Lampe, Alexander L Linqwister, William B Welte, Jeffrey R Gould, Karen L Moodie, Christopher L Kaufman, Norman A Paradis
Journal: Circulation (2018)

Background: Resuscitation from hypoxic cardiac arrest presenting with pseudo-electromechanical dissociation (P-EMD) may be associated with hypotension after ROSC. This hypotension may be refractory to catecholamine pressors. Reversing hypotension is critical for stabilizing patients successfully resuscitated from P-EMD, so other therapeutic avenues should be explored. Hypothesis: The post-resuscitation phase after hypoxic pseudo-EMD cardiac arrest may be associated with hypocalcemia. The refractory hypotension may be responsive to intravenous calcium. Methods: Using our hypoxic pseudo-EMD swine model, we measured blood pressure, hemodynamics, and electrolytes after ROSC. In 12 animals with refractory hypotension we administered 37 boluses of intravenous calcium in the dosage range of 5 -20 mg. Physiological data were analyzed on a heartbeat by heartbeat basis. The midpoint of the calcium response was defined using change of curvature feature detection. Hemodynamic parameters were shifted such that the value at the midpoint was equal to zero. Comparisons were made between the average values in the time period 40-35 seconds before the bolus and 35-40 seconds after the bolus. Results: Of the 37 administered boluses, 34 manifested a reaction in the aortic blood pressure. Mean aortic pressure, systolic and diastolic pressures all increased due to the calcium bolus. Aggregating the timepoints in the range -40 s to -36 s and comparing with the timepoints in the range 36 s to 40 s shows that the mean aortic pressure increased 11.2 ± 0.6 mmHg, the systolic pressure increased 16.2 ± 0.8 mmHg, and the diastolic pressure increased 8.0 ± 0.5 mmHg. Conclusions: Resuscitation from hypoxic pseudo-EMD is often associated with hypotension and hypocalcemia. Administration of intravenous calcium is associated with an abrupt pressor-like response. Calcium as a therapeutic in this setting should be further studied.
A radiologist's point of view
Authors: M. J. Homer
Journal: JAMA (1981)

AFTER the clinician indicates the examination he wants on the x-ray requisition, there are four choices he has regarding what to do about the section of the form reserved for clinical information. This space will either (1) remain blank, (2) contain incorrect clinical information, (3) contain correct clinical information totally irrelevant to the examination being requested, or (4) contain information that is appropriate to the examination ordered. Having spent the last eight years as a radiologist in three different medical centers, seven community hospitals, and four private offices, it is apparent to me that the options chosen do not relate to the setting of either academia or private practice. It is a function of the individual rather than a function of the institution. Some physicians view the x-ray requisition as an order to the radiologist to perform a particular imaging procedure, and the radiologist's role is to perform the examination